Surgical Innovations Group (LSE:SUN), a UK designer and maker of instruments for minimally invasive surgery, has reported a small loss for the first half of 2026 and a change of chief executive in the same week. Revenue was broadly stable, so why did the AIM-quoted medical technology company move from a modest profit to a loss?
A minimally invasive surgery specialist
Surgical Innovations Group is quoted on AIM under the ticker SUN. It designs and manufactures its own SI-branded instruments for laparoscopic and other minimally invasive procedures, makes products for other device companies through an OEM business, and distributes third-party products in the UK through its Elemental Healthcare subsidiary. The UK, and particularly the NHS, is its largest market, although it also sells in Europe, the United States and Asia-Pacific.
What the half-year report showed
On 30 September 2026, the company published its half-year report for the six months ended 30 June 2026. Revenue was £6.019 million, compared with £6.145 million a year earlier. The mix changed noticeably. SI Brand revenue fell 10.6% to £3.08 million, while distribution revenue rose 11.1% to £1.938 million and OEM revenue increased 5.0% to £1.001 million.
Because distributed third-party products typically carry lower margins than own-brand instruments, the shift towards distribution helps explain the reported decline in gross Margin to 29.0% from 31.2%. Adjusted EBITDA fell to £0.03 million from £0.37 million, and the company recorded an operating loss of £0.23 million and a loss before tax of £0.248 million, against a small profit in the first half of 2025.
By region, UK revenue increased 2.7% to £3.672 million and Asia-Pacific grew 29.3% to £0.622 million, which the company attributed mainly to strength in Japan. Europe fell 20.9% during a distributor transition, and US revenue declined 22.6%, with the report citing tariffs and a distributor Warehouse relocation.
Balance sheet and Leadership change
Cash fell to £0.361 million at 30 June 2026 from £0.813 million at the end of 2025, and net Debt was £0.309 million. The company had used £0.67 million of a £1.0 million invoice financing facility. Net Assets were £7.398 million. Elemental Healthcare's sales were £2.75 million, broadly flat against £2.80 million, and the company said it had completed MDR certification and successfully concluded UKCA and MDSAP audits. The directors stated that the group has "adequate resources to operate for the foreseeable future".
On 28 September 2026, the company announced that Alex Warnock would become chief executive from 1 October 2026, with David Marsh moving to a non-executive role after nine years in executive positions. Mr Warnock's previous roles include positions at SDI Group, Gooch & Housego and Optos. Chairman Roy Davis said he "has the right skillset to execute on our future plans".
Outlook and risks
Management said it expects a return to growth in the second half, supported by new third-party products, Investment in a rebuilt 15-person UK sales team, recovery in Europe and planned product launches, including Logitube Lux, Logi Dissect, Logi Grasp and the YelloPort Balloon Port. The report also noted the implementation of the NHS Supply Chain MIS 3 framework and associated pricing changes from August 2026.
Risks include continued Tariff pressure in the US, which the company described as "unlikely to ease significantly in the near term", the effect of NHS pricing changes on margins, the thin cash position and execution risk under new leadership.
Conclusion
Surgical Innovations Group moved into a first-half loss mainly because sales of its higher-margin own-brand products fell while lower-margin distribution grew, reducing gross margin and leaving little room above overheads. Weaker US and European revenue added to the pressure. The company expects better second-half trading, but the reported figures show limited financial headroom while a new chief executive takes charge.






Please wait processing your request...